Imunon Inc (IMNN)

Apr 01, 2025

DNA Vaccines Offer a New Path Beyond mRNA Technology - Technology Networks

Apr 01, 2025

Apr 01, 2025

Stacy Lindborg, PhD's Profile Page - Technology Networks

Apr 01, 2025

Mar 31, 2025

Companies To Watch: Imunon - Life Science Leader

Mar 31, 2025

Mar 28, 2025

IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer… - Zacks Small Cap Research

Mar 28, 2025

Mar 28, 2025

Imunon (NASDAQ:IMNN) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 28, 2025

Mar 25, 2025

FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment - Yahoo

Mar 25, 2025

Mar 25, 2025

Imunon (NASDAQ:IMNN) Receives “Buy” Rating from D. Boral Capital - Defense World

Mar 25, 2025

Mar 24, 2025

IMUNON advances to Phase 3 trial in ovarian cancer treatment By Investing.com - Investing.com South Africa

Mar 24, 2025

Mar 24, 2025

Imunon finalizes Phase 3 study design with FDA for IMNN-001 - TipRanks

Mar 24, 2025

Mar 24, 2025

IMUNON advances to Phase 3 trial in ovarian cancer treatment - Investing.com India

Mar 24, 2025

Mar 24, 2025

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - GlobeNewswire

Mar 24, 2025

Mar 24, 2025

Breakthrough Ovarian Cancer Treatment Shows 46-Month Survival as FDA Clears Phase 3 Trial - Stock Titan

Mar 24, 2025

Mar 07, 2025

IMUNON’s IMNN-101 Vaccine Shows Promising Results in Phase 1 Trial, Demonstrates Cross-Reactivity Against COVID Variants - Contagionlive.com

Mar 07, 2025

Mar 03, 2025

Imunon, Inc. Earnings Call: Clinical Success Amid Financial Challenges - TipRanks

Mar 03, 2025

Mar 02, 2025

Imunon’s (IMNN) “Buy” Rating Reiterated at D. Boral Capital - Defense World

Mar 02, 2025

Feb 28, 2025

Imunon’s Strategic Clinical Advancements and Promising Research Drive Buy Rating - TipRanks

Feb 28, 2025

Feb 28, 2025

Imunon, Inc. (NASDAQ:IMNN) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 28, 2025

Feb 28, 2025

H.C. Wainwright lifts Imunon stock target to $14 on Phase 3 plans By Investing.com - Investing.com South Africa

Feb 28, 2025

Feb 28, 2025

H.C. Wainwright lifts Imunon stock target to $14 on Phase 3 plans - Investing.com

Feb 28, 2025

Feb 28, 2025

Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges - Yahoo Finance

Feb 28, 2025

Feb 28, 2025

IMUNON, Inc. Reports 2024 Financial Results and Advances Clinical Programs - TipRanks

Feb 28, 2025

Feb 27, 2025

Earnings call transcript: Imunon Q4 2024 reports improved EPS, stock declines - Investing.com

Feb 27, 2025

Feb 27, 2025

Imunon Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025

Feb 27, 2025

IMUNON Reports 2024 Financial Results and Provides Business Update - TradingView

Feb 27, 2025

Feb 27, 2025

IMUNON Reports 2024 Financial Results and Provides Business - GlobeNewswire

Feb 27, 2025

Feb 27, 2025

IMUNON's Cancer Immunotherapy Shows 13-Month Survival Benefit in Ovarian Cancer | IMNN Stock News - StockTitan

Feb 27, 2025

Feb 27, 2025

Imunon reports immunogenicity and safety data from DNA plasmid vaccine trial - Yahoo Finance

Feb 27, 2025

Feb 26, 2025

Imunon announces new analyses of results from Phase 1 trial of IMNN-101 - TipRanks

Feb 26, 2025

Feb 26, 2025

IMUNON Announces New Immunogenicity Data from Phase 1 - GlobeNewswire

Feb 26, 2025

Feb 26, 2025

Can IMUNON's DNA Vaccine Outperform mRNA COVID Shots? New Clinical Data Reveals Key Advantages - StockTitan

Feb 26, 2025

Feb 22, 2025

Imunon (IMNN) Expected to Announce Quarterly Earnings on Thursday - Defense World

Feb 22, 2025

Feb 20, 2025

Imunon Inc [IMNN] Shares Jump Approximately 66.98% Over the Year - Knox Daily

Feb 20, 2025

Feb 20, 2025

The time has not yet come to remove your chips from the table: Imunon Inc (IMNN) - SETE News

Feb 20, 2025

Feb 20, 2025

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 - The Manila Times

Feb 20, 2025

Feb 20, 2025

IMUNON, Inc. to Announce Full Year 2024 Financial Results on February 27, 2025 - Nasdaq

Feb 20, 2025

Feb 20, 2025

New Phase II data confirm promise of Imunon’s IMMN-001 - The Pharma Letter

Feb 20, 2025

Feb 20, 2025

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer - GlobeNewswire

Feb 20, 2025

Feb 19, 2025

Imunon Announces Translational Data From Phase 1/2 Ovation 2 Study Of Imnn-001 In Advanced Ovarian Cancer - Marketscreener.com

Feb 19, 2025

Feb 19, 2025

Ovarian Cancer Breakthrough? New Drug Shows 13-Month Survival Advantage in Clinical Trial - StockTitan

Feb 19, 2025

Feb 11, 2025

IMUNON names Douglas Faller as chief medical officer - MSN

Feb 11, 2025

Feb 11, 2025

IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire

Feb 11, 2025

Feb 10, 2025

Imunon names industry vet Douglas Faller as CMO - The Pharma Letter

Feb 10, 2025

Feb 10, 2025

Imunon Appoints Dr. Douglas Faller as CMO - TipRanks

Feb 10, 2025

Jan 30, 2025

Imunon director Donald Braun acquires $29,480 worth of shares - MSN

Jan 30, 2025

Jan 26, 2025

Analyzing Imunon (NASDAQ:IMNN) & Unicycive Therapeutics (NASDAQ:UNCY) - Defense World

Jan 26, 2025

Jan 24, 2025

Biotech's Target Price 183.757% Higher Than Current - Streetwise Reports

Jan 24, 2025